Ehave (EHVVF) Announces Inclusion in the 2021 Psychedelic Investor Guide
MIAMI, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic...
Investor Presentation Slides From Dyadic (DYA) $6.40.
Really, How Do We Do It?
Live Short Term Chart
Smart for Life (SMFL) Reports, Headlines and More.
Smart For Life Corporate Investor Center
2022, 28-11. ($0.40) Smart for Life (SMFL) Announces...
IMAC Holdings (BACK) Explodes 94% Higher Post Reverse Split, With 42 Million Shares Trading...
Simply Incredible! 2024 Will be the Year of Post Reverse Split Revenge!
Taking advantage of post reverse-split investor...
The Extraordinary Dr. Koffman, Who Beat Leukemia.
Dr. Brian Koffman is extraordinary, in many ways. He’s extraordinary in the medical sense because, after twelve years of battling blood...
Is David Dodd on to his Next Billion Dollar Payday for Shareholders?
Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors.
GeoVax (GOVX) Completes Patient...
VERU Inc. (VERU) $24. High Risk, Minimal Reward?
Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders.
You Can't Kiss all the...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy...